35 | MASIMO
WHAT IT DOES:
Produces noninvasive monitoring technologies that significantly improve patient care. HOW IT GREW:
Masimo’s SET technology, which offers the ability to monitor different elements of a patient’s blood without invasive surgery, has been making strides in the field of pulse oximetry. In 2005, Masimo introduced the Rainbow SET Pulse Co-Oximetry technology, and it has continued to produce innovative technologies. According to a company news release, more than 100 independent studies have found that the SET technology provides the most reliable measurements for peripheral oxygen saturation and pulse-rates in the country, which has reduced false alarms and increased the detection of life-threatening events.
A report published in the Lancet in July called pulse oximetry a “new milestone” in the war on critical congenital heart disease. The meta-analysis pooled the results of 13 studies to conclude that pulse oximetry provides a significant improvement over existing methods in detecting babies with critical congenital heart disease.